Climb Bio, Inc. 8-K

What Happened

• Climb Bio, Inc. filed an 8-K (Item 5.02) announcing that Senior Vice President, Finance and principal accounting officer Cindy Driscoll and the company mutually agreed on April 1, 2026 that she will separate from the company, effective April 30, 2026.
• The company’s Chief Financial Officer, Susan Altschuller, Ph.D., MBA, who has served as CFO since October 2025, will also assume the role of principal accounting officer effective April 30, 2026.

Key Details

• Departure announced: mutual agreement reached April 1, 2026; separation effective April 30, 2026.
• New principal accounting officer: Susan Altschuller, Ph.D., MBA (CFO since Oct 2025).
• Background on Altschuller: prior CFO roles at Dragonfly Therapeutics (Aug–Dec 2024), Cerevel Therapeutics (May 2023–Aug 2024), ImmunoGen (Jul 2020–Mar 2023); earlier roles at Alexion. She holds a BSE (Tulane), a Ph.D. in biomedical engineering, and an MBA from MIT Sloan.
• No changes to Dr. Altschuller’s compensation arrangements were reported; she has no family relationships with company officers or directors and no reportable related-party transactions under Item 404(a).

Why It Matters

• This filing confirms a finance leadership transition: the company is removing its SVP Finance/principal accounting officer and consolidating accounting oversight under the existing CFO. For investors, that signals continuity of finance and accounting leadership without a separate hire for the principal accounting officer role and without disclosed compensation changes.
• The disclosure is procedural and regulatory (8‑K Item 5.02) and provides background on the new principal accounting officer to help assess experience and potential continuity in financial reporting and internal controls.